2 insiders bought €11.5M of shares over the last 90 days, the latest filed 14 Aug 2026.
This page follows insider dealings at Idorsia Ltd as filed with SIX SER based in Switzerland. The group dates from 2017. Over the twelve months to 18 October 2026, 6 filings were filed, from 2 insiders.
Both sides are active: 4 purchases worth €11.5M and 2 sales worth €108k, from 2 insiders and 2 insiders respectively. Taken together, the purchases exceed the sales by €11.4M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 senior executives. The largest single trade was a purchase of €4.7M, published on 14 August 2026, equal to 0.36% of the market capitalisation.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 14 August 2026, which is 64 days ago. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade.
Across the 178 companies tracked on its exchange, the median is 9 filings; at 6 filings, this issuer sits below that mark. Over the whole record (from 2026), the tally stands at 4 purchases and 2 sales.
This summary is built from SIX SER disclosures alone and does not predict where the share price will go.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Idorsia Ltd Buy (bullish), based on 3 analysts. Average price target: CHF 5.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
6 of 6 declarations
Idorsia Ltd is a Swiss biopharmaceutical company focused on the research and development of innovative treatments for central nervous system disorders and other conditions. It is listed on the Swiss Stock Exchange under the ticker IDIA.
Headquarters: Switzerland · Founded: 2017 · Wikipedia article
Source: Wikidata (CC0).